Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2016
At a glance
- Drugs Rabies vaccine (Primary)
- Indications Rabies
- Focus Adverse reactions
- Sponsors CureVac
- 28 Jul 2016 Planned End Date changed from 1 Mar 2016 to 1 Oct 2016.
- 28 Jul 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Aug 2016.
- 01 Dec 2015 Status changed from recruiting to active, no longer recruiting as per Clinicaltrials.gov record.